1. Home
  2. GNLX

as 05-30-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Founded: 2001 Country:
United States
United States
Employees: N/A City: WESTLAKE VILLAGE
Market Cap: 94.0M IPO Year: 2023
Target Price: $17.75 AVG Volume (30 days): 159.0K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.88 EPS Growth: N/A
52 Week Low/High: $1.60 - $5.88 Next Earning Date: 05-06-2025
Revenue: N/A Revenue Growth: -95.29%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

GNLX Daily Stock ML Predictions

Stock Insider Trading Activity of Genelux Corporation (GNLX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Zindrick Thomas GNLX President and CEO May 12 '25 Sell $2.92 10,764 $31,430.88 191,447
Ryder Sean GNLX General Counsel May 12 '25 Sell $2.92 4,475 $13,067.00 47,621
Smalling Ralph GNLX Head of Regulatory May 12 '25 Sell $2.92 1,259 $3,676.28 34,760
Cappello Joseph GNLX VP, Pharmaceutical Development May 12 '25 Sell $2.92 4,737 $13,832.04 52,266

Share on Social Networks: